Humacyte (NASDAQ:HUMA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Friday, MarketBeat Ratings reports. HC Wainwright currently has a $15.00 price target on the stock, up from their prior price target of $12.00.

A number of other research analysts have also recently issued reports on the company. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and an average target price of $13.43.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $4.64 on Friday. The company has a 50 day simple moving average of $4.83 and a two-hundred day simple moving average of $5.85. Humacyte has a fifty-two week low of $2.48 and a fifty-two week high of $9.97. The company has a market capitalization of $583.99 million, a price-to-earnings ratio of -3.46 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock worth $6,606,799 over the last quarter. Company insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in Humacyte in the 2nd quarter worth approximately $28,000. Concurrent Investment Advisors LLC bought a new stake in Humacyte in the 3rd quarter valued at $75,000. Principal Financial Group Inc. purchased a new stake in Humacyte in the 2nd quarter worth $83,000. FORA Capital LLC bought a new position in shares of Humacyte during the 3rd quarter valued at about $96,000. Finally, Profund Advisors LLC purchased a new position in shares of Humacyte during the second quarter valued at about $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.